2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Sarcoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Oligodendroglioma
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Leukemia
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Cyclophosphamide
45
Prednisone
31
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
29
Vincristine
28
Doxorubicin
27
Etoposide
22
romidepsin
20
Gemcitabine
18
Lenalidomide
16
10-propargyl-10-deazaaminopterin
16
fludarabine phosphate
15
Whole-Body Irradiation
15
Peripheral Blood Stem Cell Transplantation
14
Brentuximab Vedotin
14
Azacitidine
13
Mycophenolic Acid
12
Dexamethasone
10
Cyclosporine
10
Bortezomib
10
Alemtuzumab
10
Rituximab
8
fludarabine
7
belinostat
7
Methotrexate
6
Cytarabine
6
Busulfan
6
Bendamustine Hydrochloride
6
pembrolizumab
5
denileukin diftitox
5
Nivolumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Peripheral
×
abexinostat
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts